Former executive at Albumedix Ltd
- RHA (recombinant human albumin) vs HSA (human serum albumin) and BSA (bovine serum albumin) – value proposition and biomanufacturing applications including C> (cell and gene therapy) and vaccines
- Demand outlook for rHA, synergies with Sartorius’s (ETR: SRT) existing portfolio including CellGenix, and Albumedix's growth outlook under new ownership
- Potential rationale behind Sartorius’s agreement to acquire Albumedix vs competing rHA suppliers and deal terms
- Implications for Sartorius’s competitive positioning in C> and other advanced therapies vs bioprocessing incumbents including Danaher (NYSE: DHR) and Thermo Fisher (NYSE: TMO)
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited